Association of oxidized ApoB and oxidized ApoA-I with high-risk coronary plaque features in cardiovascular disease

JCI Insight. 2023 Oct 23;8(20):e172893. doi: 10.1172/jci.insight.172893.

Abstract

Background: Oxidized apolipoprotein B (oxLDL) and oxidized ApoA-I (oxHDL) are proatherogenic. Their prognostic value for assessing high-risk plaques by coronary computed tomography angiography (CCTA) is missing.

Methods: In a prospective, observational study, 306 participants with cardiovascular disease (CVD) had extensive lipoprotein profiling. Proteomics analysis was performed on isolated oxHDL, and atherosclerotic plaque assessment was accomplished by quantitative CCTA.

Results: Patients were predominantly White, overweight men (58.5%) on statin therapy (43.5%). Increase in LDL-C, ApoB, small dense LDL-C (P < 0.001 for all), triglycerides (P = 0.03), and lower HDL function were observed in the high oxLDL group. High oxLDL associated with necrotic burden (NB; β = 0.20; P < 0.0001) and fibrofatty burden (FFB; β = 0.15; P = 0.001) after multivariate adjustment. Low oxHDL had a significant reverse association with these plaque characteristics. Plasma oxHDL levels better predicted NB and FFB after adjustment (OR, 2.22; 95% CI, 1.27-3.88, and OR, 2.80; 95% CI, 1.71-4.58) compared with oxLDL and HDL-C. Interestingly, oxHDL associated with fibrous burden (FB) change over 3.3 years (β = 0.535; P = 0.033) when compared with oxLDL. Combined Met136 mono-oxidation and Trp132 dioxidation of HDL showed evident association with coronary artery calcium score (r = 0.786; P < 0.001) and FB (r = 0.539; P = 0.012) in high oxHDL, whereas Met136 mono-oxidation significantly associated with vulnerable plaque in low oxHDL.

Conclusion: Our findings suggest that the investigated oxidized lipids are associated with high-risk coronary plaque features and progression over time in patients with CVD.

Clinicaltrials: gov NCT01621594.

Funding: National Heart, Lung, and Blood Institute at the NIH Intramural Research Program.

Keywords: Atherosclerosis; Cardiology; Cardiovascular disease; Inflammation; Lipoproteins.

Publication types

  • Observational Study

MeSH terms

  • Apolipoprotein A-I
  • Apolipoproteins B
  • Cardiovascular Diseases*
  • Cholesterol, LDL
  • Humans
  • Male
  • Plaque, Atherosclerotic* / diagnostic imaging
  • Prospective Studies

Substances

  • Apolipoprotein A-I
  • Apolipoproteins B
  • Cholesterol, LDL
  • APOA1 protein, human
  • APOB protein, human

Associated data

  • ClinicalTrials.gov/NCT01621594

Grants and funding

The funding sources had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.